[go: up one dir, main page]

AR106940A1 - ANTI CLAUDINE ANTIBODIES AND METHODS OF USE - Google Patents

ANTI CLAUDINE ANTIBODIES AND METHODS OF USE

Info

Publication number
AR106940A1
AR106940A1 ARP160103710A ARP160103710A AR106940A1 AR 106940 A1 AR106940 A1 AR 106940A1 AR P160103710 A ARP160103710 A AR P160103710A AR P160103710 A ARP160103710 A AR P160103710A AR 106940 A1 AR106940 A1 AR 106940A1
Authority
AR
Argentina
Prior art keywords
seq
established
claudine
antibodies
methods
Prior art date
Application number
ARP160103710A
Other languages
Spanish (es)
Inventor
A Williams Samuel
A Stull Robert
Natwarsinhji Sisodiya Vikram
Fong Sarah
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of AR106940A1 publication Critical patent/AR106940A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 7: El conjugado de anticuerpo y fármaco de las reivindicaciones 1 ó 2 que comprende un anticuerpo anti-CLDN que comprende o compite por la unión a una proteína CLDN humana con un anticuerpo caracterizado porque comprende una región variable de cadena liviana (VL) establecida como la SEQ ID Nº 61 y una región variable de cadena pesada (VH) establecida como la SEQ ID Nº 63 (hSC27.1); o una VL establecida como la SEQ ID Nº 65 y una VH establecida como la SEQ ID Nº 67 (hSC27.22); o una VL establecida como la SEQ ID Nº 69 y una VH establecida como la SEQ ID Nº 71 (hSC27.108); o una VL establecida como la SEQ ID Nº 73 y una VH establecida como la SEQ ID Nº 75 (hSC27.204); o una VL establecida como la SEQ ID Nº 73 y una VH establecida como la SEQ ID Nº 77 (hSC27.204v2).Claim 7: The antibody and drug conjugate of claims 1 or 2 comprising an anti-CLDN antibody comprising or competing for binding to a human CLDN protein with an antibody characterized in that it comprises an established light chain variable region (VL) such as SEQ ID No. 61 and a heavy chain variable region (VH) established as SEQ ID No. 63 (hSC27.1); or a VL established as SEQ ID No. 65 and a VH established as SEQ ID No. 67 (hSC27.22); or a VL established as SEQ ID No. 69 and a VH established as SEQ ID No. 71 (hSC27.108); or a VL established as SEQ ID No. 73 and a VH established as SEQ ID No. 75 (hSC27.204); or a VL established as SEQ ID No. 73 and a VH established as SEQ ID No. 77 (hSC27.204v2).

ARP160103710A 2015-12-04 2016-12-02 ANTI CLAUDINE ANTIBODIES AND METHODS OF USE AR106940A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562263542P 2015-12-04 2015-12-04

Publications (1)

Publication Number Publication Date
AR106940A1 true AR106940A1 (en) 2018-03-07

Family

ID=61768558

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103710A AR106940A1 (en) 2015-12-04 2016-12-02 ANTI CLAUDINE ANTIBODIES AND METHODS OF USE

Country Status (1)

Country Link
AR (1) AR106940A1 (en)

Similar Documents

Publication Publication Date Title
DOP2020000128A (en) ANTI-TREM2 ANTIBODIES AND RELATED METHODS
CY1125260T1 (en) TIGIT COMMITMENT FACTORS AND THEIR USES
CY1125327T1 (en) ANTI-PD-1 ANTIBODIES AND COMPOSITIONS
CO2019012210A2 (en) Anti-trem2 antibodies and methods of using them
CO2018003852A2 (en) Antigen binding proteins that activate the leptin receptor
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
DOP2018000259A (en) BISPECIFIC UNION PROTEINS THAT JOIN AN IMMUNOMODULATORY PROTEIN AND A TUMORAL ANTIGEN
CL2018003136A1 (en) Specific binding proteins and uses thereof.
CL2017000278A1 (en) Bispecific t-cell activating antigen binding molecules
AR102554A1 (en) ANTI-CLDN ANTIGEN CHEMERIC RECEIVERS AND METHODS OF USE
MX375032B (en) BINDING PROTEINS AND METHODS OF USING THEM.
CL2018001000A1 (en) Antibodies and antibody conjugates and anti-egfr drug.
PE20240111A1 (en) BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF
CL2017000545A1 (en) Anti-her2 and immunoconjugate antibodies
CU20160101A7 (en) IMMUNOGLOBULINA WITH FAB IN TANDEM
MX2021007006A (en) Humanised anti kallikrein-2 antibody.
MX2021007768A (en) ANTI-CTLA4 ANTIBODIES AND METHODS OF USE THEREOF.
MX2017012802A (en) ANTISORTILINE ANTIBODIES AND METHODS FOR USE.
MX2020004801A (en) Bispecific fusion polypeptides and methods of use thereof.
PE20161210A1 (en) ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE
MX351127B (en) Oncostatin m receptor antigen binding proteins.
CL2015003174A1 (en) Anti-igf-1r antibodies with abolition of fcrn binding and its use in the treatment of vascular eye diseases
MX382809B (en) USE OF TM9SF4 AS A BIOMARKER FOR TUMOR-ASSOCIATED EXOSOMES.
AR101671A1 (en) ANTIBODIES ANTI PROTEIN SIMILAR TO ANGIOPOYETINA-4 (ANGPTL4) AND METHODS OF USE
AR099604A1 (en) METALOPROTEINASE MATRIX 9 ANTIBODIES AND THEIR METHODS OF USE

Legal Events

Date Code Title Description
FB Suspension of granting procedure